Cargando…
Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc
c-Myc is a transcription factor that is constitutively and aberrantly expressed in over 70% of human cancers. Its direct inhibition has been shown to trigger rapid tumor regression in mice with only mild and fully reversible side effects, suggesting this to be a viable therapeutic strategy. Here we...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780693/ https://www.ncbi.nlm.nih.gov/pubmed/33397405 http://dx.doi.org/10.1186/s12943-020-01291-6 |
_version_ | 1783631552866942976 |
---|---|
author | Madden, Sarah K. de Araujo, Aline Dantas Gerhardt, Mara Fairlie, David P. Mason, Jody M. |
author_facet | Madden, Sarah K. de Araujo, Aline Dantas Gerhardt, Mara Fairlie, David P. Mason, Jody M. |
author_sort | Madden, Sarah K. |
collection | PubMed |
description | c-Myc is a transcription factor that is constitutively and aberrantly expressed in over 70% of human cancers. Its direct inhibition has been shown to trigger rapid tumor regression in mice with only mild and fully reversible side effects, suggesting this to be a viable therapeutic strategy. Here we reassess the challenges of directly targeting c-Myc, evaluate lessons learned from current inhibitors, and explore how future strategies such as miniaturisation of Omomyc and targeting E-box binding could facilitate translation of c-Myc inhibitors into the clinic. |
format | Online Article Text |
id | pubmed-7780693 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-77806932021-01-05 Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc Madden, Sarah K. de Araujo, Aline Dantas Gerhardt, Mara Fairlie, David P. Mason, Jody M. Mol Cancer Review c-Myc is a transcription factor that is constitutively and aberrantly expressed in over 70% of human cancers. Its direct inhibition has been shown to trigger rapid tumor regression in mice with only mild and fully reversible side effects, suggesting this to be a viable therapeutic strategy. Here we reassess the challenges of directly targeting c-Myc, evaluate lessons learned from current inhibitors, and explore how future strategies such as miniaturisation of Omomyc and targeting E-box binding could facilitate translation of c-Myc inhibitors into the clinic. BioMed Central 2021-01-04 /pmc/articles/PMC7780693/ /pubmed/33397405 http://dx.doi.org/10.1186/s12943-020-01291-6 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Madden, Sarah K. de Araujo, Aline Dantas Gerhardt, Mara Fairlie, David P. Mason, Jody M. Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc |
title | Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc |
title_full | Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc |
title_fullStr | Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc |
title_full_unstemmed | Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc |
title_short | Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc |
title_sort | taking the myc out of cancer: toward therapeutic strategies to directly inhibit c-myc |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780693/ https://www.ncbi.nlm.nih.gov/pubmed/33397405 http://dx.doi.org/10.1186/s12943-020-01291-6 |
work_keys_str_mv | AT maddensarahk takingthemycoutofcancertowardtherapeuticstrategiestodirectlyinhibitcmyc AT dearaujoalinedantas takingthemycoutofcancertowardtherapeuticstrategiestodirectlyinhibitcmyc AT gerhardtmara takingthemycoutofcancertowardtherapeuticstrategiestodirectlyinhibitcmyc AT fairliedavidp takingthemycoutofcancertowardtherapeuticstrategiestodirectlyinhibitcmyc AT masonjodym takingthemycoutofcancertowardtherapeuticstrategiestodirectlyinhibitcmyc |